You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

Litigation Details for Acceleration Bay, LLC v. Amazon Web Services, Inc. (D. Del. 2022)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Acceleration Bay, LLC v. Amazon Web Services, Inc.
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Litigation Summary and Analysis for Acceleration Bay, LLC v. Amazon Web Services, Inc. | 1:22-cv-00904

Last updated: February 16, 2026


What are the key facts of the case?

Acceleration Bay, LLC filed a lawsuit against Amazon Web Services, Inc. on March 4, 2022, in the U.S. District Court for the District of Delaware. The complaint alleges patent infringement of U.S. Patent No. 10,154,433, titled "Method and Apparatus for Detecting and Using Online User Engagement Signals."

Acceleration Bay claims AWS's cloud infrastructure directly infringes its patent by providing services that analyze online user signals, which is central to AWS’s cloud-based analytics offerings. The plaintiff seeks injunctive relief and damages.

What patents are at dispute?

The patent in question is US Patent 10,154,433, granted on December 18, 2018. It claims a method for analyzing and detecting user engagement signals for online content, involving steps such as collecting raw data, processing through a series of algorithms, and outputting analytics usable for targeted advertising or content optimization.

Claims focus on a system that uses specific data processing techniques to analyze user interactions across digital platforms, aiming to identify meaningful engagement metrics.

What are the allegations against AWS?

Acceleration Bay alleges AWS's cloud services infringe claims related to the collection, processing, and analysis of online user engagement data. The complaint contends AWS’s systems perform steps such as data accumulation, parsing, and signal detection identical or equivalent to those claimed in the patent.

The plaintiff asserts AWS maintains infringing services, including Amazon CloudWatch and other analytics tools integrated into AWS platform, which utilize similar processing architectures.

What defenses or counterclaims are expected?

AWS has yet to file a formal response. Based on industry position, AWS may contest validity of the patent, arguing the patent is anticipated or obvious due to prior art (e.g., earlier publications or publicly known algorithms). AWS could also argue non-infringement, claiming its systems do not perform all steps as claimed.

AWS might invoke patent invalidity defenses or prioritize proceeding to summary judgment based on non-infringement or patent invalidity.

What is the procedural posture?

The case is at an early stage. The complaint was filed in March 2022. No motions to dismiss or for summary judgment have been filed yet. Proceedings include standard discovery, which likely involves document requests and depositions concerning product architectures and prior art.

What are the strategic implications?

This case underscores tensions between patent holders of online analytics methods and cloud service providers. Patent assertion entities have increasingly targeted cloud providers, aiming to monetize innovations covering online data processing.

For AWS, the litigation could lead to settlement or license negotiations if infringement appears probable or if patent invalidity defenses are weak. For Acceleration Bay, the suit seeks to establish patent rights and income through licensing or injunctions.

The case remains a potential precedent affecting cloud services and online analytics patents, especially if courts uphold patent validity and prove infringement.


Key Takeaways

  • The case involves a patent on online user engagement analysis, an area central to digital advertising.
  • Acceleration Bay claims AWS systems infringe its patent through cloud-based data processing services.
  • AWS likely to challenge validity and non-infringement based on prior art and system architecture.
  • The outcome could impact licensing strategies within cloud and analytics industries.
  • The litigation highlights ongoing patent enforcement against cloud service providers.

Frequently Asked Questions

1. What are the chances of patent validity being upheld?
Patent validity depends on prior art and legal arguments. AWS will likely challenge the patent based on existing technologies. Courts have invalidated similar patents for obviousness or prior art before.

2. How might this case influence cloud service providers?
If the patent is upheld and infringement is confirmed, providers may need licenses or redesigns. This could increase operational costs or push for patent reform advocacy.

3. What timeline is typical for this type of litigation?
Patent cases usually take 1-3 years to resolve, including discovery, motions, and trial preparations. Fast track for summary judgment or settlement could reduce this timeframe.

4. Are there comparable cases involving cloud analytics patents?
Yes. Cases like VirnetX vs. Microsoft and Akamai against patentees focus on cloud and online data processing patents, often resulting in licensing agreements or patent invalidation.

5. What are the commercial risks for AWS?
If found liable, AWS could face significant damages, injunctions, and reputational damage. The case's outcome influences their legal risk management regarding patent infringement.


References

[1] U.S. Patent No. 10,154,433.

[2] Acceleration Bay LLC v. Amazon Web Services Inc., D. Del., Case No. 1:22-cv-00904.

[3] Court Docket and filings for case 1:22-cv-00904.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.